MY150518A - Substituted gamma lactams as therapeutic agents - Google Patents

Substituted gamma lactams as therapeutic agents

Info

Publication number
MY150518A
MY150518A MYPI20105007A MY150518A MY 150518 A MY150518 A MY 150518A MY PI20105007 A MYPI20105007 A MY PI20105007A MY 150518 A MY150518 A MY 150518A
Authority
MY
Malaysia
Prior art keywords
therapeutic agents
substituted gamma
lactams
gamma lactams
substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Danny T Dinh
David W Old
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MY150518A publication Critical patent/MY150518A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20105007 2008-04-24 2009-04-22 Substituted gamma lactams as therapeutic agents MY150518A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4750108P 2008-04-24 2008-04-24

Publications (1)

Publication Number Publication Date
MY150518A true MY150518A (en) 2014-01-30

Family

ID=40852537

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20105007 MY150518A (en) 2008-04-24 2009-04-22 Substituted gamma lactams as therapeutic agents

Country Status (19)

Country Link
US (1) US7820661B2 (enExample)
EP (1) EP2291368B1 (enExample)
JP (1) JP5524181B2 (enExample)
KR (1) KR20110008263A (enExample)
CN (1) CN102076681A (enExample)
AU (1) AU2009239372B2 (enExample)
BR (1) BRPI0911347A2 (enExample)
CA (1) CA2722529A1 (enExample)
CO (1) CO6321273A2 (enExample)
DK (1) DK2291368T3 (enExample)
ES (1) ES2399314T3 (enExample)
IL (1) IL208899A0 (enExample)
MX (1) MX2010011636A (enExample)
MY (1) MY150518A (enExample)
PL (1) PL2291368T3 (enExample)
RU (1) RU2543379C2 (enExample)
UA (1) UA103616C2 (enExample)
WO (1) WO2009132088A1 (enExample)
ZA (1) ZA201007553B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2009236356A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
WO2009132097A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2009249388B2 (en) * 2008-05-20 2014-04-03 Allergan, Inc. Therapeutic lactams
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
KR20180021919A (ko) 2009-11-09 2018-03-05 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
AU2013306012B2 (en) * 2012-08-21 2018-02-08 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
JP6662864B2 (ja) * 2014-10-02 2020-03-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ガンマ−ラクタムのエステルプロドラッグ及びそれらの使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US395798A (en) * 1889-01-08 reason
US4007210A (en) 1973-04-27 1977-02-08 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanates
US3985798A (en) 1975-01-27 1976-10-12 American Cyanamid Company 11α-HOMO-PROSTANOIC ACIDS AND ESTERS
US4060540A (en) 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3876050T2 (de) 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk Okulare hypotensivagenzien.
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6034413A (en) * 1997-02-27 2000-03-07 Texas Instruments Incorporated High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
DE60208568T2 (de) 2001-07-16 2006-10-05 F. Hoffmann-La Roche Ag Prostaglandinanaloga als ep4-rezeptoragonisten
WO2003040126A1 (en) 2001-11-05 2003-05-15 Allergan, Inc. φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS
TW200305425A (en) * 2002-03-05 2003-11-01 Ono Pharmaceutical Co 8-Azaprostaglandin derivatives and medicament containing same as active ingredient
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2483555A1 (en) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
WO2004037813A1 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
BRPI0518563A2 (pt) * 2004-12-22 2008-11-25 Janssen Pharmaceutica Nv moduladores de delta-opiàide tricÍclicos
DK1856042T3 (da) * 2005-03-10 2012-09-17 Allergan Inc Substituerede gamma-lactamer som terapeutiske midler
WO2007005176A1 (en) 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
KR101422305B1 (ko) 2006-08-11 2014-07-22 알러간, 인코포레이티드 치료학적 락탐
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
EP2121672B1 (en) * 2007-01-31 2014-12-10 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
WO2009132097A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
EP2291368B1 (en) 2012-12-19
AU2009239372A1 (en) 2009-10-29
MX2010011636A (es) 2010-11-25
BRPI0911347A2 (pt) 2018-03-20
KR20110008263A (ko) 2011-01-26
ES2399314T3 (es) 2013-03-27
US7820661B2 (en) 2010-10-26
IL208899A0 (en) 2011-01-31
UA103616C2 (ru) 2013-11-11
DK2291368T3 (da) 2013-03-18
JP5524181B2 (ja) 2014-06-18
CA2722529A1 (en) 2009-10-29
WO2009132088A1 (en) 2009-10-29
US20090270392A1 (en) 2009-10-29
CN102076681A (zh) 2011-05-25
AU2009239372B2 (en) 2013-09-19
JP2011518833A (ja) 2011-06-30
RU2010144637A (ru) 2012-05-27
ZA201007553B (en) 2011-08-31
PL2291368T3 (pl) 2013-05-31
RU2543379C2 (ru) 2015-02-27
EP2291368A1 (en) 2011-03-09
CO6321273A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
MY150518A (en) Substituted gamma lactams as therapeutic agents
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
EA201170521A1 (ru) Новые соединения
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX339759B (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
IN2012DN02556A (enExample)
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY185134A (en) 6-substituted phenoxychroman carboxylic acis derivatives
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
IN2012DN03844A (enExample)
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea